Summit Therapeutics plc Summit Therapeutics To Present At The 2019 Bio Investor Forum

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Therapeutics to Present at the 2019 BIO Investor Forum 
 
   Oxford, UK, and Cambridge, MA, US, 16 October 2019 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn 
Edwards, Chief Executive Officer, will present at the 2019 BIO Investor 
Forum on 22 October 2019 at 10:45am PDT in San Francisco. 
 
   A live webcast of the presentation will be available in the Investors 
section of the Company's website, 
https://www.globenewswire.com/Tracker?data=yy_XElWCR05esQ--N0WsFpdLvIgE8iIevZpknMz9Ly-0m4Qw6eFRLGm5H-jncTzPJB4CxJ1HSjL6qxa0RFbWfxPnt-C9OCUdnAtzY2Rmtc0= 
www.summitplc.com. A replay of the webcast will be available from the 
same location soon after the live presentation. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)     Tel:                  44 (0)1235 443 951 
Michelle Avery (US office)                                          +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                  Tel:                 +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                  Tel:                 +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)  Tel:                 +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                             Tel:                     +1 781 684 6652 
                                                         mailto:summit@mslgroup.com 
Erin Anthoine                                                   summit@mslgroup.com 
                                                  --------------------------------- 
 
Consilium Strategic Communications (UK)    Tel:                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Sukaina          mailto:summit@consilium-comms.com 
 Virji                                             summit@consilium-comms.com 
                                                  --------------------------------- 
Lindsey Neville 
 
 
   -END-

(END) Dow Jones Newswires

October 16, 2019 07:00 ET (11:00 GMT)

Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025